指南与共识食管胃疾病与幽门螺杆菌

AGA临床实践更新:成人艰难梭菌感染管理专家评述

AGA Clinical Practice Update on Management of Clostridioides difficile Infection in Adults: Expert Review.
指南 / 共识 · Clin Gastroenterol Hepatol · 2026-07-01

美国胃肠病协会(AGA)发布成人艰难梭菌感染(CDI)管理临床实践更新,基于专家意见和文献综述提出14条最佳实践建议。内容涵盖感染预防、诊断检测、严重程度分类、初发与复发治疗、粪菌移植及暴发性CDI的多学科管理。

要点

  • 非暴发性CDI首选非达霉素,万古霉素为可接受替代,甲硝唑仅用于暴发性疾病。
  • CDI诊断需结合临床症状与多步实验室检测,Discordant但高临床疑似者应治疗。
  • 暴发性CDI需多学科团队管理,采用大剂量万古霉素联合静脉甲硝唑,肠梗阻时加用直肠万古霉素。

核心结论

  • AGA专家评述提出14条成人CDI管理最佳实践建议,涵盖预防、诊断、治疗及复发管理。

研究设计与样本

  • 由AGA临床实践更新委员会和AGA理事会委托的专家评述,基于专家意见和已发表文献综述制定,未进行系统评价,建议无正式证据质量或推荐强度分级。

主要发现

  • 白细胞计数>15,000 cells/uL和/或肌酐>1.5倍基线提示严重CDI及复发和不良结局风险增加。
  • 非达霉素200 mg每日两次口服10天因复发率较低被推荐为非暴发性CDI一线治疗,万古霉素125 mg每日四次口服10天亦可接受。
  • 甲硝唑不应在暴发性疾病之外使用。
  • 首次复发(完成抗CDI治疗后8周内第二 episode)应使用万古霉素逐渐减量方案或非达霉素治疗。
  • 第二次复发(第三 episode)治疗后应提供粪菌微生物疗法(fecal microbiota spores, live-brpk、fecal microbiota, live-jslm或传统粪菌移植)。

关键数值与推荐

  • 住院CDI患者诊断时应分类为非严重、严重或暴发性疾病。
  • 严重CDI指标:白细胞计数>15,000 cells/uL和/或肌酐>1.5倍基线;暴发性CDI额外表现包括休克、肠梗阻或巨结肠。
  • 非达霉素200 mg每日两次口服10天;万古霉素125 mg每日四次口服10天。
  • 暴发性CDI:万古霉素500 mg每6小时口服或肠内给药,联合甲硝唑500 mg每8小时静脉给药;肠梗阻时加用直肠万古霉素500 mg每6小时。
  • 多次复发且不适合粪菌微生物疗法者,可考虑万古霉素125 mg每日一次长期低剂量抑制性方案用于二级预防。

临床怎么用

  • CDI诊断需兼容症状(通常为抗生素后急性腹泻)结合支持性实验室检测,多步检测首选。
  • 非暴发性CDI首选非达霉素,万古霉素为可接受替代;甲硝唑仅用于暴发性疾病。
  • 治疗后不进行常规治愈检测,仅在腹泻症状持续加重时行粪便检测。
  • 治疗CDI或预防复发时应评估质子泵抑制剂使用,有正当适应症者无需停药。
  • 有CDI病史者应特别告知避免不必要的抗生素治疗。

局限性

  • 未进行系统评价,最佳实践建议无正式证据质量或推荐强度分级。
  • 建议基于专家意见和文献综述,非系统评价结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DESCRIPTION: Clostridioides difficile infection is a common cause of clinically significant diarrhea, often becomes recurrent, and can be fatal when severe or fulminant. The purpose of this America Gastroenterological Association (AGA) Clinical Practice Update Expert Review is to provide best practice advice for C difficile infection management. METHODS: This expert review was commissioned by the AGA Institute Clinical Practice Updates Committee and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership. The review was developed from expert opinion and a review of the published literature. Because systematic reviews were not performed, these best practice advice statements do not carry formal ratings regarding the quality of evidence or strength of the presented considerations. The review underwent internal peer review by the Practice Updates Committee and external peer review through standard procedures of Clinical Gastroenterology and Hepatology. BEST PRACTICE ADVICE STATEMENTS BEST PRACTICE ADVICE 1: Prevention of C difficile infection should include proper barrier protection and disinfection with United States Environmental Protection Agency-approved sporicidal agents in health care settings. Patients should be counseled on the importance of handwashing and to consider disinfecting areas of the home potentially contaminated with C difficile spores, to prevent reinfection. Reassurance should be provided that C difficile infection transmission to unaffected family members is uncommon. BEST PRACTICE ADVICE 2: C difficile infection is a clinical diagnosis that requires compatible symptoms (typically acute diarrhea, following antibiotics) in combination with supportive laboratory testing. Multistep testing is preferred for best diagnostic accuracy; however, patients with discordant testing who have a high clinical suspicion for C difficile infection should be treated. BEST PRACTICE ADVICE 3: Clinicians should classify hospitalized patients with C difficile infection as having nonsevere, severe, or fulminant disease at diagnosis. White blood cell count >15,000 cells/uL and/or creatinine >1.5 × baseline are indicative of severe C difficile infection and increased risk for recurrence and poor outcomes. Patients with additional findings of shock, ileus, or megacolon have fulminant C difficile infection, which can be fatal. BEST PRACTICE ADVICE 4: Fidaxomicin (200 mg twice daily oral for 10 days) is a narrower spectrum agent, and given lower recurrence rates, is favored as first-line therapy for nonfulminant C difficile infection. However, given practical considerations, vancomycin (125 mg 4 times daily oral for 10 days) is also acceptable therapy. Metronidazole should not be used outside of fulminant disease. BEST PRACTICE ADVICE 5: Cholestyramine and other bile acid-binding agents should not be used as monotherapy or concurrently with oral vancomycin or fidaxomicin. Psyllium fiber can be used to bulk stools in patients who have recovered from the infection. BEST PRACTICE ADVICE 6: Following treatment of C difficile infection, clinicians should not perform routine test of cure. Stool testing should only be performed for persistent worsening of diarrheal symptoms. BEST PRACTICE ADVICE 7: First C difficile infection recurrence (second episode) within 8 weeks of completing anti-C difficile infection therapy should be treated with either a tapering course of vancomycin or fidaxomicin. Treatment of C difficile infection should include a risk assessment for C difficile infection recurrence and consideration of microbiota restoration therapy to prevent recurrence. BEST PRACTICE ADVICE 8: Fecal microbiota-based therapies (fecal microbiota spores, live-brpk, fecal microbiota, live-jslm, or conventional fecal microbiota transplant) should be offered after treatment of a second recurrence (third C difficile infection episode). Microbiota restoration therapy may be considered after treatment of an initial infection or first recurrence in patients who are at high risk for further recurrence or in patients whose initial C difficile infection episode was particularly morbid or difficult to treat. BEST PRACTICE ADVICE 9: Prolonged, low dose, suppressive vancomycin regimen (125 mg daily) for secondary prophylaxis may be considered in patients with multiple recurrent episodes who are not candidates for fecal microbiota-based therapies due to ongoing comorbidities, limited life expectancy, or ongoing/frequent systemic antibiotics or who have failed multiple courses of fecal microbiota-based therapy. BEST PRACTICE ADVICE 10: Fulminant C difficile infection should be managed by a multidisciplinary team (gastroenterology/infectious disease, surgery, medicine/critical care) and treated with high-dose vancomycin 500 mg every 6 hours (oral or enteral), with metronidazole 500 mg intravenously every 8 hours, and if ileus is present, rectal vancomycin 500 mg every 6 hours should be added. BEST PRACTICE ADVICE 11: Multi-dose fecal microbiota transplantation (fresh-directed donors, or institutional stool banks) delivered via lower endoscopy, should be considered in individuals with fulminant C difficile infection. Fecal microbiota, live-jslm (Rebyota), and fecal microbiota spores, live-brpk (Vowst) have not been studied and are not approved for treatment of severe and/or fulminant C difficile infection. Due to high risk of C difficile infection recurrence, patients who recover from severe or fulminant C difficile infection should be maintained on a suppressive vancomycin regimen until a final fecal microbiota transplantation can be administered as an outpatient. BEST PRACTICE ADVICE 12: Use of vancomycin is not advised during systemic antibiotic administration to prevent C difficile infection. Probiotics are not advised to prevent an initial or recurrent C difficile infection. To promote restoration of healthy gut microbiota, patients should be instructed to consume a healthy diet including a variety of fruits and vegetables, rich in both soluble and insoluble fiber. BEST PRACTICE ADVICE 13: During the treatment of C difficile infection or the prevention of its recurrence, the use of proton pump inhibitors should be evaluated. If a legitimate indication exists for their use, proton pump inhibitor discontinuation is not necessary. BEST PRACTICE ADVICE 14: Individuals with a history of C difficile infection should be specifically counseled to avoid unnecessary antibiotic therapy.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Fischer M, Vaughn BP, Peery AF, et al. AGA Clinical Practice Update on Management of Clostridioides difficile Infection in Adults: Expert Review. Clin Gastroenterol Hepatol. 2026. PMID: 42383946. doi:10.1016/j.cgh.2026.05.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。